Streetbeat News

Stock Prices

GPK

Graphic Packaging Holding (NYSE:GPK) has seen a 17.51% increase in short interest since its last report, with 12.96 million shares sold short, representing 5.37% of its float. This indicates a bearish market sentiment, although it's higher than the peer group average of 2.99%. The coverage time for these short positions is approximately 4.62 days based on current trading volumes.

Portfolio Pulse from Benzinga Insights

April 26, 2024 | 6:45 pm

ABBV

CI

CVS

Evernorth Health Services, a subsidiary of The Cigna Group (NYSE:CI), announced its Accredo arm will offer a Humira biosimilar with no out-of-pocket costs to patients. This initiative, starting in June, is expected to save patients an average of $3,500 annually. The biosimilar, produced for Quallent Pharmaceuticals, is priced about 85% lower than Humira, AbbVie Inc's (NYSE:ABBV) arthritis drug. Despite the introduction of biosimilars, AbbVie has retained over 98% of the Humira market. CVS Health Inc's (NYSE:CVS) pharmacy benefits unit has begun shifting prescriptions to biosimilars, impacting Humira's market share.

Portfolio Pulse from Vandana Singh

April 26, 2024 | 6:41 pm

MOG/A

Moog Inc. shares surged following the announcement of its Q2 financial results, which exceeded expectations. Additionally, the company has uplifted its FY24 guidance above the initial estimates, signaling a positive outlook for its future performance.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 6:38 pm

BTI

MO

PM

SPY

The U.S. Health Secretary announced that the proposed rule to ban menthol cigarettes will require more time for implementation. This delay affects major tobacco companies and could impact their stock prices in the short term.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 6:38 pm

MOG.A

Moog shares are trading higher, indicating a positive movement in the stock's price.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 6:38 pm

MBLY

NVDA

QCOM

Mobileye Global Inc (NASDAQ:MBLY) reported a significant 48% year-on-year revenue decline for Q1, attributed to stiff competition and a surprising downturn in EV adoption. Analyst Adam Jonas from Morgan Stanley downgraded Mobileye's rating from Equal-Weight to Underweight and lowered the price target from $26 to $25, citing limited near-term growth potential for its SuperVision product due to reduced EV adoption and increased competition from companies like Nvidia Corp (NASDAQ:NVDA), Qualcomm Inc (NASDAQ:QCOM), and others exploring ADAS technologies.

Portfolio Pulse from Priya Nigam

April 26, 2024 | 6:36 pm

DJT

Trump Media & Technology Group (NASDAQ:DJT), after its SPAC merger with Digital World Acquisition Corporation, has seen its stock fluctuate significantly. Short sellers and investors buying put options have reportedly made $200 million in paper profits as the stock declined from its peak. Despite a high cost to borrow and a significant portion of the float being shorted, the stock has recently gained, partly due to news on short selling and Trump's ongoing legal issues. Trump owns a majority in the company, which complicates potential stock sales and short selling strategies.

Portfolio Pulse from Chris Katje

April 26, 2024 | 6:34 pm

GOLD

Recent analysis of Barrick Gold (NYSE:GOLD) options trading shows a bullish sentiment among financial giants, with 57% of traders leaning bullish and 43% bearish. The analysis highlighted unusual trading activity, including 21 notable trades, with a focus on a price range of $11.0 to $25.0 for Barrick Gold over the last 3 months. The largest trades observed include both bullish and bearish sentiments across various expiration dates. Barrick Gold, a major gold miner, has seen its stock price increase by 0.7% to $17.2, with an RSI suggesting it may be approaching overbought territory. An earnings release is anticipated in 5 days, and BMO Capital maintains an Outperform rating with a target price of $26.

Portfolio Pulse from Benzinga Insights

April 26, 2024 | 6:31 pm

VKTX

Viking Therapeutics (NASDAQ:VKTX) has seen significant options trading activity, with a bullish sentiment prevailing among financial giants. Analysis revealed 27 unusual trades, with a majority being calls. The trading activity suggests a focus on a price band between $20.0 and $115.0. The company, specializing in biopharmaceutical development for metabolic and endocrine disorders, is currently trading up by 4.23% at $71.77. Analyst ratings from HC Wainwright & Co. have set a target price at $90.0.

Portfolio Pulse from Benzinga Insights

April 26, 2024 | 6:31 pm

ELV

Elevance Health (NYSE:ELV) has delivered an average annual return of 15.39% over the past 5 years, outperforming the market by 3.78% annually. With a current market capitalization of $125.43 billion, a $100 investment in ELV 5 years ago would now be worth $202.11. This performance highlights the impact of compounded returns on investment growth over time.

Portfolio Pulse from Benzinga Insights

April 26, 2024 | 6:30 pm